Semaphorins are mainly known as guidance signals in development, acting through receptors called Plexins. However, their role in cancer is rapidly emerging in the regulation of tumor angiogenesis, tumor growth, cancer cell invasiveness, and metastatic spreading. Intriguingly, activated plexins can transactivate receptor tyrosine kinases, such as MET, VEGFR2, FGFR2, and ERBB2, and lead to distinctive effects in a cell-context-dependent manner. Moreover, certain semaphorins concomitantly target endothelial and cancer cells, and can achieve remarkable inhibition of angiogenesis and tumor growth, associated with anti-metastatic activity. Altogether, these data validate the identification of semaphorin signals as promising therapeutic targets in cancer.

Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer.

TAMAGNONE, Luca
2012-01-01

Abstract

Semaphorins are mainly known as guidance signals in development, acting through receptors called Plexins. However, their role in cancer is rapidly emerging in the regulation of tumor angiogenesis, tumor growth, cancer cell invasiveness, and metastatic spreading. Intriguingly, activated plexins can transactivate receptor tyrosine kinases, such as MET, VEGFR2, FGFR2, and ERBB2, and lead to distinctive effects in a cell-context-dependent manner. Moreover, certain semaphorins concomitantly target endothelial and cancer cells, and can achieve remarkable inhibition of angiogenesis and tumor growth, associated with anti-metastatic activity. Altogether, these data validate the identification of semaphorin signals as promising therapeutic targets in cancer.
2012
22
2
145
152
http://www.sciencedirect.com/science/article/pii/S1535610812003029
EGF; tumor angiogenesis; structural basis; Actin cytoskeleton; pancreatic cancer; dependent manner; Cell Migration; Plexin B1; Receptors; expression
Tamagnone L
File in questo prodotto:
File Dimensione Formato  
2012_Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer.pdf

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 553.12 kB
Formato Adobe PDF
553.12 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/124648
Citazioni
  • ???jsp.display-item.citation.pmc??? 73
  • Scopus 126
  • ???jsp.display-item.citation.isi??? 121
social impact